The FDA issued a statement in February, warning Americans that “preliminary results from an initial safety clinical trial” on Xeljanz showed an increased risk of serious heart-related problems as a result of the medication. This medication—which is an arthritis and ulcerative colitis drug classified under the generic name tofacitinib—was compared by the administration to another type of medication called a tumor necrosis factor (TNF) inhibitor, which also treats arthritis. According to the trial findings, Xeljanz also increases someone’s risk of cancer when compared to those treated with a TNF inhibitor instead. And for more medication concerns, If You’re Taking Tylenol With This, Your Liver Is in Danger, Experts Say. Xeljanz was approved by the FDA in 2012 to treat rheumatoid arthritis (RA) in patients who did not respond well to another rheumatoid arthritis medicine, methotrexate. Then, in 2017, the FDA also approved Xeljanz to treat patients with psoriatic arthritis (PsA) who also did not response well to methotrexate or other similar medications. Finally, in 2018, the FDA approved the medication to treat another condition called ulcerative colitis, which is a chronic inflammatory disease affecting the colon. “Tofacitinib works by decreasing the activity of the immune system; an overactive immune system contributes to RA, PsA, and ulcerative colitis,” the FDA stated. And for more up-to-date information, sign up for our daily newsletter.ae0fcc31ae342fd3a1346ebb1f342fcb In Feb. 2019 and July 2019, the FDA warned that interim trial results showed an increased risk of blood clots and death from using Xeljanz at a higher (10 milligram) twice-daily dosage. According to the medication’s information page from the FDA, patients treated with Xeljanz are also at an “increased risk for developing serious infections that may lead to hospitalization or death.” Reported infections that have occurred include active tuberculosis, invasive fungal infections, as well as bacterial and viral infections. And for more medication warnings, The FDA Released a New Warning About This OTC Pain Reliever.
Xeljanz was created by the company Pfizer, who reported that this medication was the most prescribed JAK inhibitor to treat moderate to severe rheumatoid arthritis as of May 2020. And as of 2019, the company reported that approximately 196,000 patients in the U.S. had been treated for either rheumatoid arthritis, psoriatic arthritis, or ulcerative colitis using Xeljanz. Despite the warnings, the FDA is asking that anyone prescribed Xeljanz not stop taking it on their own. “Patients should not stop taking tofacitinib without first consulting with your health care professionals, as doing so may worsen your condition,” the administration said in their warning. “Talk to your health care professionals if you have any questions or concerns.” However, if you do experience sudden shortness of breath, chest pain that worsens with breathing, swelling of a leg or arm, leg pain or tenderness, or red or discolored skin in the painful or swollen leg or arm, the FDA does ask that you temporarily stop taking tofacitinib and seek emergency medical care immediately, as these may be symptoms of a blood clot. And for more on your heart health, If You See This on Your Skin, Your Heart Attack Risk Is Higher, Study Says.
